Some US drug developers jump after FDA announces recipients of national priority vouchers
** Shares of drug developers Revolution Medicines RVMD up 11.7% at $55.48, Achieve Life Sciences'
ACHV gains 34.4% to 4.13%, and Disc Medicine's
IRON rises 28.3% to $95.43
** Late on Thursday, U.S. FDA announced nine products under a new fast-track review process
** Selected drugs could get approval within one to two months of filing a complete application; typical review time is 10 to 12 months
** Products include RVMD's daraxonrasib for pancreatic cancer, ACHV's cytisinicline for nicotine dependence related to e-cigarette or vaping use and IRON's bitopertin for porphyria
** Brokerage Oppenheimer says daraxonrasib's first approval could come as early as mid-2026
** Eli Lilly's LLY experimental weight-loss pill, orforglipron, was expected to be included in the list
** Separately, Trump signaled the price of LLY's Danish rival Novo Nordisk's weight-loss drug would be lowered
** LLY shares down 2.1%
** Including session moves, RVMD up 24.3%, IRON up 40%, LLY up ~3% and ACHV up 9.9% YTD